Medicare Part D – Page 31 – medicarereport.org

A trusted source for Medicare news and education from the AMAC Foundation.

The New Help for Medicare Beneficiaries with High Drug Costs That Few Seem to Know About

(By Juliette Cubanski and Tricia Neuman for the Kaiser Family Foundation Published: Dec 12, 2023) The Inflation Reduction Act of

Eileen Cook December 14, 2023December 14, 2023 CMS, Healthcare Costs, Inflation Reduction Act of 2022, medicare, Medicare Advantage, Medicare Part D, Older Adults, Out-of-pocket prescription costs

CMS Health Care Finance Health Care Redesign Health Insurance Legislative Update Medical Debt Medicare - General Part D/Prescription Drugs Price Transparency

3 Inflation Reduction Act Medicare changes taking effect in 2024

(By Rylee Wilson for Becker’s Hospital Review ) The federal government will cap drug copays and premiums for Medicare beneficiaries

Eileen Cook December 12, 2023December 12, 2023 CMS, Drug price Transparency, Healthcare Costs, Inflation Reduction Act of 2022, medicare, Medicare Insulin Cost-sharing, Medicare Part D, Older Adults

Health Care Finance Health Care Redesign Legislative Update Medicare - General Part D/Prescription Drugs Price Transparency

House passes site-neutral policy, transparency, PBM reform package

(By Rachel Cohrs for ST A T) WASHINGTON — The House passed a relatively major health care package late Monday,

Eileen Cook December 12, 2023December 12, 2023 Healthcare Finance, medicare, Medicare Part D, PBM, Price Transparency, Site Neutral Policy

CMS Health Care Finance Health Care Redesign Legislative Update Medicare - General Medicare Advantage Part D/Prescription Drugs Price Transparency

Medicare bills pass House committee: 3 things to know

(By Rylee Wilson for Becker’s Hospital Review ) The House Energy and Commerce Committee advanced 19 pieces of legislation Dec.

Eileen Cook December 11, 2023December 11, 2023 Drug price Transparency, Healthcare Costs, medicare, Medicare Advantage, Medicare Advantage transparency, Medicare Part D, PBM

FDA Health Care Finance Legal Actions/Court Decisions Legislative Update Part D/Prescription Drugs

White House proposes to ‘march in’ on patents for costly drugs

(By Sydney Lupkin for NPR) The Biden administration is taking another crack at high prescription drug prices. This time its

Eileen Cook December 8, 2023December 8, 2023 Bayh-Dole Act of 1980, Biomedical research, Healthcare Costs, March In Rights, Medicare Part D, Prescription drug costs, Prescription Drug Patents

CMS Health Care Finance Medicare Advantage

Is the Medicare Advantage ‘gold rush’ over?

(By Rylee Wilson for Becker’s Hospital Review ) The Medicare Advantage gold rush is slowing down, Wall Street Journal columnist

Eileen Cook December 7, 2023December 7, 2023 CMS, medicare, Medicare Advantage, Medicare Part D, Mergers, Older Adults

FDA Legislative Update Part D/Prescription Drugs

Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports

(By Phil Galewitz for KFF Health News) Colorado officials say their plan to import cheaper medicines from Canada has been

Eileen Cook December 7, 2023December 7, 2023 Drug Imports, Drugmakers, FDA, Medicare Part D

Health Care Finance Part D/Prescription Drugs

The Mark Cuban effect on drug pricing

(By Paige Twenter for Becker’s Hospital Review ) In January 2022, entrepreneur and “Shark Tank” star Mark Cuban launched an

Eileen Cook December 6, 2023December 6, 2023 Drug costs, Drug price Transparency, Medicare Part D

CMS Medicare - General Medicare Advantage Part D/Prescription Drugs

Uncle Sam Wants You … to Help Stop Insurers’ Bogus Medicare Advantage Sales Tactics

(By Susan Jaffe for KFF Health News) After an unprecedented crackdown on misleading advertising claims by insurers selling private Medicare

Eileen Cook November 30, 2023November 30, 2023 CMS, medicare, Medicare Advantage, Medicare Advantage Ads, Medicare Part D, Older Adults

Alzheimer’s/Dementia FDA Medicare - General Part D/Prescription Drugs

Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect

(By Madhav Thambisetty for ST A T) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision

Eileen Cook November 28, 2023November 28, 2023 Aducanumab, Alzheimer’s Disease, ARIA, CMS, Dementia, Donanemab, FDA, Lecanemab Drug, medicare, Medicare Part D, Older Adults